Flexion therapeutics, inc. (FLXN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenues
Product revenue, net

72,957

22,524

355

-

-

-

-

-

Revenue

-

-

-

-

-

-

0

0

Operating expenses
Cost of sales

9,960

7,336

4

-

-

-

-

-

Research and development

69,559

53,079

51,231

41,314

32,691

17,923

11,060

11,065

Selling, general and administrative

129,709

121,311

78,801

28,466

13,372

9,063

6,704

3,946

Total operating expenses

209,228

181,726

130,036

69,780

46,063

26,987

17,765

15,011

Loss from operations

-136,271

-159,202

-129,681

-69,780

-46,063

-26,987

-17,765

-15,011

Other (expense) income
Interest income

3,212

4,567

3,718

1,521

1,246

478

233

193

Interest expense

17,066

15,712

11,268

1,748

571

401

448

-

Other expense

-

-

-

-

927

-

-

-

Other income

352

688

-250

-1,887

-

-403

-206

-163

Total other (expense) income

-13,502

-10,457

-7,800

-2,114

-252

-326

-421

30

Net loss

-149,773

-169,659

-137,481

-71,894

-46,315

-27,313

-18,186

-14,981

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-14,981

Net loss per common share, basic and diluted

-3.93

-4.49

-4.16

-2.84

-2.15

-1.97

-23.02

-27.58

Weighted average common shares outstanding, basic and diluted

38,086

37,751

33,027

25,297

21,497

13,893

790

543

Other comprehensive (loss) income:
Unrealized (losses) gains from available-for-sale securities, net of tax of $0

139

330

-336

26

-92

-5

-2

1

Total other comprehensive (loss) income

139

330

-336

26

-92

-5

-2

1

Comprehensive loss

-149,634

-169,329

-137,817

-71,868

-46,407

-27,318

-18,189

-14,979